AstraZeneca
rare disease highlights advancing expansion of in nephrology data supports initiation of potential phase trial mean spot weeks rapid complete and sustained complement inhibition at week potential disease modifying reduction in proteinuria significant unmet need for patients on | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
29 of 45
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io